BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11846143)

  • 1. Global views on leukodepletion, bacterial testing, viral removal/inactivation: Germany.
    Seitz R; Montag T
    Transfus Apher Sci; 2001 Dec; 25(3):203-4. PubMed ID: 11846143
    [No Abstract]   [Full Text] [Related]  

  • 2. Leucodepletion, bacterial testing and pathogen removal update and position for Scotland: April 2001.
    Prowse CV
    Transfus Apher Sci; 2001 Dec; 25(3):217-8. PubMed ID: 11846149
    [No Abstract]   [Full Text] [Related]  

  • 3. Transfusion medicine in Norway 2001. Time for change.
    Flesland O; Solheim BG; Seghatchian J
    Transfus Apher Sci; 2001 Dec; 25(3):211-4. PubMed ID: 11846147
    [No Abstract]   [Full Text] [Related]  

  • 4. Leucodepletion, bacterial contamination and viral inactivation: a Portuguese blood centre experience.
    Vasconcelos E
    Transfus Apher Sci; 2001 Dec; 25(3):215-6. PubMed ID: 11846148
    [No Abstract]   [Full Text] [Related]  

  • 5. EPFA/NIBSC Workshop on Nucleic Acid Amplification Technology (NAT) for the detection of blood borne viruses.
    Rogers PM; Robertson JS
    Biologicals; 1998 Mar; 26(1):69-74. PubMed ID: 9637751
    [No Abstract]   [Full Text] [Related]  

  • 6. Current strategies on pathogen removal/inactivation: an overview.
    Allain JP; Seghatchian J
    Transfus Apher Sci; 2001 Dec; 25(3):195-7. PubMed ID: 11846140
    [No Abstract]   [Full Text] [Related]  

  • 7. [Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
    Cazenave JP
    Bull Acad Natl Med; 2010 Dec; 194(9):1707-19; discussion 1719-20. PubMed ID: 22043595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meeting transfusion safety expectations.
    AuBuchon JP
    Ann Intern Med; 2005 Oct; 143(7):537-8. PubMed ID: 16204166
    [No Abstract]   [Full Text] [Related]  

  • 9. Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application.
    Corash L
    Transfus Apher Sci; 2001 Dec; 25(3):179-81. PubMed ID: 11846134
    [No Abstract]   [Full Text] [Related]  

  • 10. [Safety of blood transfusions; need for 'hemo-vigilance'].
    van Aken WG; van Rood JJ
    Ned Tijdschr Geneeskd; 1998 Feb; 142(6):281-4. PubMed ID: 9562726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion. Blood cleansing deemed safe, but more donors required.
    AIDS Policy Law; 2002 Aug; 17(16):8. PubMed ID: 12236221
    [No Abstract]   [Full Text] [Related]  

  • 12. Leucodepletion (LD) trends and preferred approaches.
    Rowe G
    Transfus Apher Sci; 2001 Dec; 25(3):219-20. PubMed ID: 11846150
    [No Abstract]   [Full Text] [Related]  

  • 13. Advances in multiplex nucleic acid diagnostics for blood-borne pathogens: promises and pitfalls.
    Duncan R; Kourout M; Grigorenko E; Fisher C; Dong M
    Expert Rev Mol Diagn; 2016; 16(1):83-95. PubMed ID: 26581018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma.
    Kwon SY; Kim IS; Bae JE; Kang JW; Cho YJ; Cho NS; Lee SW
    Vox Sang; 2014 Oct; 107(3):254-60. PubMed ID: 24806328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood safety--at what cost?
    Bekker LG; Wood R
    JAMA; 2006 Feb; 295(5):557-8. PubMed ID: 16449622
    [No Abstract]   [Full Text] [Related]  

  • 16. New developments in biological standardisation: commentary on the poster session on advances in transfusion safety.
    Seghatchian J
    Dev Biol (Basel); 2002; 108():129-36. PubMed ID: 12220136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative strategies in assuring blood safety: An overview.
    Epstein JS
    Biologicals; 2010 Jan; 38(1):31-5. PubMed ID: 20110174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging infectious risks of blood transfusions.
    Busch MP; Kleinman SH; Nemo GJ
    JAMA; 2003 Feb; 289(8):959-62. PubMed ID: 12597733
    [No Abstract]   [Full Text] [Related]  

  • 19. Nanoceramics for blood-borne virus removal.
    Zhao Y; Sugiyama S; Miller T; Miao X
    Expert Rev Med Devices; 2008 May; 5(3):395-405. PubMed ID: 18452389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blood - surely but safely!].
    Offergeld R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Aug; 55(8):905-6. PubMed ID: 22842882
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.